Profusa, a developer of tissue-integrating biosensors designed to assist continuous monitoring of body chemistry, agreed to go public via a SPAC merger with NorthView Acquisition in a $264m. "We believe our merger with Profusa represents a rare opportunity to partner with a management team and business that is highly sought after to be a public company with a true platform solution, globally focused and with technology validated via product approval and ready for launch. We are confident that this business combination will provide Profusa or the Combined Company with the financial resources to launch its commercial plans for its oxygen biosensor product, seek FDA approval for its continuous glucose monitoring product and continue to develop near term revenue opportunities to leverage its novel tissue integrated biosensor technology platform," Jack Stover, NorthView CEO.